HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation-Reference-Cited by-同舟云学术

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation

Published:2012-09-05 Issue:10 Volume:2 Page:922-933
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Takezawa Ken,Pirazzoli Valentina,Arcila Maria E.,Nebhan Caroline A.,Song Xiaoling,de Stanchina Elisa,Ohashi Kadoaki,Janjigian Yelena Y.,Spitzler Paula J.,Melnick Mary Ann,Riely Greg J.,Kris Mark G.,Miller Vincent A.,Ladanyi Marc,Politi Katerina,Pao William

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 607 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer;Cancer Letters;2024-11

2. Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy;European Journal of Pharmacology;2024-10

3. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents;Bioorganic Chemistry;2024-10

4. pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance;Acta Biochimica et Biophysica Sinica;2024-09-01

5. Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review;Frontiers in Oncology;2024-08-09